A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
Clinical trial NCT05787613 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05787613
- Sponsor
- Shanghai Henlius Biotech
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-10
- Primary completion
- 2026-02-01
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.